Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review

Donnez, Jacques; Courtoy, Guillaume E.; Donnez, Olivier; Dolmans, Marie-Madeleine

doi:10.1016/j.rbmo.2018.04.040

Cited by 34 publications

(22 citation statements)

References 42 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The appropriateness of employing an antiprogestin-activated transactivator in a RCCV-based vaccine may need to be re-evaluated in light of more recent developments. Pivotal clinical trials demonstrated that ulipristal is capable of reducing the size of uterine fibroids, resulting in marketing approvals of the ulipristal-containing drug Esmya (Gedeon Richter Plc, Budapest, Hungary) in Europe and Canada [43][44][45]. A typical treatment involves one or more treatment cycles of up to three months (5 mg/day of ulipristal taken orally).…”

Section: Additional Thoughts On the Antiprogestin Co-control Of Rccvsmentioning

confidence: 99%

Herpes Simplex Viruses Whose Replication Can Be Deliberately Controlled as Candidate Vaccines

Voellmy¹,

Bloom

Vilaboa

2020

Vaccines

View full text Add to dashboard Cite

Over the last few years, we have been evaluating a novel paradigm for immunization using viruses or virus-based vectors. Safety is provided not by attenuation or inactivation of vaccine viruses, but by the introduction into the viral genomes of genetic mechanisms that allow for stringent, deliberate spatial and temporal control of virus replication. The resulting replication-competent controlled viruses (RCCVs) can be activated to undergo one or, if desired, several rounds of efficient replication at the inoculation site, but are nonreplicating in the absence of activation. Extrapolating from observations that attenuated replicating viruses are better immunogens than replication-defective or inactivated viruses, it was hypothesized that RCCVs that replicate with wild-type-like efficiency when activated will be even better immunogens. The vigorous replication of the RCCVs should also render heterologous antigens expressed from them highly immunogenic. RCCVs for administration to skin sites or mucosal membranes were constructed using a virulent wild-type HSV-1 strain as the backbone. The recombinants are activated by a localized heat treatment to the inoculation site in the presence of a small-molecule regulator (SMR). Derivatives expressing influenza virus antigens were also prepared. Immunization/challenge experiments in mouse models revealed that the activated RCCVs induced far better protective immune responses against themselves as well as against the heterologous antigens they express than unactivated RCCVs or a replication-defective HSV-1 strain. Neutralizing antibody and proliferation responses mirrored these findings. We believe that the data obtained so far warrant further research to explore the possibility of developing effective RCCV-based vaccines directed to herpetic diseases and/or diseases caused by other pathogens.

show abstract

Section: Additional Thoughts On the Antiprogestin Co-control Of Rccvsmentioning

confidence: 99%

Herpes Simplex Viruses Whose Replication Can Be Deliberately Controlled as Candidate Vaccines

Voellmy¹,

Bloom

Vilaboa

2020

Vaccines

View full text Add to dashboard Cite

show abstract

“…Hormonal medical treatment for uterine fibroids include combined oral contraceptives, levonorgestrel intrauterine device (LNG-IUD), progestins, gonadotropinreleasing hormone (GnRH) agonists, androgenic steroids, and selective progesterone receptor modulators (SPRMs) (Donnez et al 2018;Esmya 2012;Laughlin-Tommaso 2016;Lumsden et al 2015;Singh et al 2018;Vilos et al 2015).…”

Section: Medical Treatmentmentioning

confidence: 99%

Uterine Fibroids and Adenomyosis

Gràcia¹,

Carmona²

2020

Endocrinology

View full text Add to dashboard Cite

Uterine fibroids and adenomyosis are common gynecological conditions in patients presenting abnormal uterine bleeding (AUB), pain (dysmenorrhea and dyspareunia), and infertility. Uterine fibroids are benign myometrial tumors, and, conversely, adenomyosis is characterized by the presence of heterotopic endometrial glands and stroma within the myometrium. Although being different entities, they share symptoms and treatment options. Clinical characteristics and main diagnosis criteria for uterine fibroids and adenomyosis will be developed. Nowadays, treatment for fibroids and adenomyosis is intended to control symptoms trying to preserve future fertility up to menopausal status. In this chapter, we will review main management options currently available: surgical treatment (including radical and conservative surgery), nonsurgical options, and medical treatment. Lastly, both conditions are common among women of reproductive age, and they can alter fertility and pregnancy outcomes. Thus, in the last part, adenomyosis-related and myoma-related infertility will be reviewed, as long as reproduction implications.

show abstract

“…Отмечено, что у некоторых пациенток, получавших терапевтическую дозу УПА, могут наблюдаться признаки идиосинкразического ЛПП с потенциально серьезными клиническими последствиями в связи с повышенной чувствительностью к препарату. К сожалению, в настоящее время не известны биомаркеры, которые можно было бы использовать для выявления таких пациенток до начала лечения [32,33].…”

Section: селективные модуляторы прогестероновых рецепторовunclassified

Non-surgical treatment of uterine fibroids. Efficacy of the selective progesterone receptor modulator

Dovletkhanova¹,

Mezhevitinova

Прилепская

2019

Med. sov.

View full text Add to dashboard Cite

The leading role of ovarian steroid hormones in the pathogenesis of uterine fibroids is confirmed by epidemiological, clinical and experimental studies. The new approaches to the treatment of this disease may be developed on the basis of the biological and genetic mechanisms underlying the occurrence and development of leiomyomas. The use of ulipristal acetate in patients with uterine leiomyoma may be a promising method for preparing them to the surgical procedures, but also for avoiding surgical treatment and related hypoestrogenic conditions, which results in the improvement of the women’s quality of life.

show abstract

Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review

Cited by 34 publications

References 42 publications

Herpes Simplex Viruses Whose Replication Can Be Deliberately Controlled as Candidate Vaccines

Herpes Simplex Viruses Whose Replication Can Be Deliberately Controlled as Candidate Vaccines

Uterine Fibroids and Adenomyosis

Non-surgical treatment of uterine fibroids. Efficacy of the selective progesterone receptor modulator

Contact Info

Product

Resources

About